J Korean Ophthalmol Soc.  2011 Jan;52(1):34-40. 10.3341/jkos.2011.52.1.34.

Long-term Therapeutic Effect of Intravitreal Bevacizumab (Avastin) on Myopic Choroidal Neovascularization

Affiliations
  • 1Department of Ophthalmology, Dankook University Hospital, Cheonan, Korea. changmh@dankook.ac.kr

Abstract

PURPOSE
To evaluate the long-term therapeutic effects of intravitreal bevacizumab on myopic choroidal neovascularization (CNV).
METHODS
Medical records of 6 patients who underwent intravitreal bevacizumab injection for myopic CNV and were followed for more than 2 years, were retrospectively investigated. The best corrected visual acuity was compared at 1,3,12, and 24 months after injection. Two years after the injection, a fluorescein angiography and optical coherence tomography (OCT) were performed to evaluate the central macular thickness and leakage of CNV.
RESULTS
The mean best corrected visual acuity was 1.16 +/- 0.43 (logMAR), 0.45 +/- 0.21 (logMAR), 0.29 +/- 0.23 (logMAR), 0.14 +/- 0.11 (logMAR), and 0.11 +/- 0.06 (logMAR) at baseline, 1, 3, 12, and 24 months after injection, respectively.
CONCLUSIONS
Intravitreal bevacizumab injection for the treatment of myopic CNV was effective in maintaining postoperative visual acuity for 2 years.

Keyword

Bevacizumab; Choroidal neovascularization; Intravitreal injection; Long-term; Myopic CNV
Full Text Links
  • JKOS
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr